Form 4: Alnylam Director Charles Sigal Receives Equity Grant

Director Charles Elliott Sigal acquired 671 restricted stock units and 1,441 stock options as part of an annual equity incentive grant.

Summary

• Director Charles Elliott Sigal was granted 671 restricted stock units (RSUs) on May 20, 2026.
• The director also received a grant of 1,441 stock options with an exercise price of $298.48.
• Both the RSUs and the stock options are scheduled to vest in full on the first anniversary of the grant date, May 20, 2027, or upon earlier retirement/resignation under specific conditions.
• Following these transactions, the director holds 1,446 shares directly and 2,000 shares indirectly through a family trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation that does not signal a change in company strategy or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Standardized vesting schedule ensures retention and long-term commitment.

Negatives

• None identified; this is a routine compensatory filing.

Risks

• Market volatility affecting the value of the granted equity.
• Potential for dilution, though these grants are standard incentive compensation.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a disclosure of director equity compensation.

Industry Context

StockSavvy.ai notes that this filing represents standard corporate governance practices within the biotechnology sector, where equity-based compensation is the primary mechanism for aligning board member incentives with company performance.

Comparison to Industry Standards

• The use of RSUs and stock options with a one-year cliff vesting period is consistent with standard compensation packages for non-employee directors in the mid-to-large cap biotech industry.
• The grant structure aligns with practices seen at peer companies like Biogen or Vertex Pharmaceuticals.

Corporate Governance

Related Party Transactions

• The reporting person holds 2,000 shares through Sigal Family Investments, LLC, where he serves as Managing Member.

Stakeholder Impact

• Minimal impact on shareholders; reflects standard board compensation.

Next Steps

• Vesting of equity grants on May 20, 2027.

Key Dates

Keywords

Alnylam Pharmaceuticals, ALNY, Form 4, Director Compensation, Equity Incentive, Insider Transaction